Vial Sealing Applications by Drug Product Type

The right vial seal depends on the drug product inside: a multidose vaccine, a high-value biologic, a lyophilised cake and a cytotoxic oncology fill each place different demands on the closure, from container closure integrity and tamper evidence to cold-chain robustness and machinability. This hub maps the main pharmaceutical applications to the closure considerations that matter for each, and to the Autofits seal that fits.

This page is for formulators, packaging engineers and sourcing managers choosing a vial closure by application. It gives an overview of how seal selection changes with the product, a mapping table you can scan, and links to the detailed application pages.

Key takeaways

Vial seal selection is application-led. The same 20 mm flip-off seal that suits a routine injectable may not be the best fit for a lyophilised biologic or a multidose vaccine.
The recurring decisions are container closure integrity (CCI), tamper evidence, machinability on the capping line, sterility and form of supply, and, where relevant, lyophilisation and cold-chain robustness.
For most injectable applications the FlipTop® Optima flip-off seal is the default; specific applications point to the Pull-Ring or Tear-Down designs.
Closure standards run across all of these: ISO 8362-6 (aluminium-plastics caps), ISO 15378 (GMP for primary packaging), USP <1207> (CCI) and EU GMP Annex 1.
Fifteen application pages are live. They are grouped below into biologics and vaccines, sterile injectables, specialty and high-risk fills, and diagnostics, reagents and animal health, so you can go straight to the drug category you are packaging.

How vial-seal selection varies by application

Every injectable vial closure does the same core job: an aluminium shell crimps under the vial neck flange, compressing the rubber stopper against the glass to form the sterile barrier. What changes from one application to the next is the set of secondary requirements layered on top of that barrier.

A multidose vaccine needs a closure the user can open quickly and identify by colour, plus tamper evidence so a punctured or opened vial is obvious. A biologic is high in value and sensitive to extractables and leachables, so the priority shifts to material compliance and demonstrable container closure integrity across the shelf life. A lyophilised product is capped after freeze-drying, often with the stopper part-seated in the lyophiliser, so machinability and a clean crimp on a partially inserted stopper matter most. A cytotoxic oncology fill demands a robust, well-defined tamper-evident seal because any breach has occupational-safety consequences as well as sterility ones.

The mechanics also differ. Most applications want a flip-off button that exposes only a small injection point while the aluminium stays crimped. Some, such as oral vaccinations or products where the whole seal must come off for full access, call for a tear-down or pull-ring design instead. Cold-chain products add a further constraint: the closure system has to keep its seal through freezing and thawing without the crimp loosening.

The table below summarises these patterns and points to the Autofits closure that fits each application.

Application to closure mapping

Application	Key closure considerations	Suggested Autofits closure
Biologics	Extractables and leachables, demonstrable CCI, high-value fill, material compliance over shelf life	FlipTop® Optima and Pull-Ring (13/20 mm)
Cell and gene therapy	Cryogenic and ultra-cold storage, freeze-thaw duty on the crimp, single-patient autologous batches, small 13 mm formats, full lot documentation	FlipTop® Optima (13/20 mm) Button design
Vaccines	Multidose vs single-dose access, fast opening, colour coding, tamper evidence, cold chain; oral vaccinations need full removal	FlipTop® Optima flip-off (13/20 mm); Tear-Down for oral vaccines
Lyophilised products	Capping on a part-seated lyophilisation stopper, clean crimp, machinability, CCI on the freeze-dried cake	FlipTop® Optima (20/28 mm)
IV diluents and saline	Terminal sterilisation duty, high-volume line economics, AQL at scale, multi-dose reseal	FlipTop® Optima (20/32 mm)
Anaesthetics	Fast single-handed opening in time-critical settings, colour coding for safe identification, multidose access	FlipTop® Optima (20 mm) Button design; Tear-Down where the whole seal comes off
Emergency and crash-cart drugs	Single-handed opening under time pressure, unambiguous colour differentiation between look-alike ampoule strengths, tamper evidence on stocked trays, long unattended shelf life	FlipTop® Optima (13/20 mm) Button design, colour coded
Insulin and hormones	Repeated puncture over an extended in-use period, stopper reseal under USP <381>, stable crimp, tamper evidence	FlipTop® Optima (13/20 mm)
Oncology and cytotoxic	Controlled opening that avoids aerosols and spills, irreversible tamper evidence, CCI on reconstituted lyophilised powders	FlipTop® Optima Button design and Pull-Ring
Ophthalmic	CCI on a small neck with little crimp margin, sterility to expiry, low particulate contribution, tamper evidence	FlipTop® Optima (13 mm)
Contrast media	Large fill volumes, full stopper access for power-injector spiking, contrast warming duty, 32 mm formats	Pull-Ring (32 mm) and FlipTop® Optima
Prefilled syringes and kits	Vial-and-syringe kits and diluent pairings, carton and tray design around the syringe, cold-chain handling, serialisation and identification across the kit	FlipTop® Optima (13/20 mm) on the vial component
Diagnostics and IVD reagents	Different regulatory pathway, colour coding across a parallel reagent panel, broad 13 to 34 mm size range	Tear-off seals and FlipTop® Optima
Research and lab reagents	RUO and laboratory use, freezer storage and freeze-thaw duty, small 13 mm formats, colour coding for fast identification	FlipTop® Optima (13 mm) and tear-off seals
Veterinary	Multidose access on large-format vials, the full 13 to 34 mm neck range, robust field handling, oral dosing in some lines	FlipTop® Optima and Tear-Down

The closure suggestions reflect current Autofits practice. Browse closures by neck size from the by-size index, most often 20 mm for injectables and 13 mm for small-volume fills, and see the full range on the products page.

The application pages, grouped by drug category

Biologics, vaccines and freeze-dried products. High-value fills where material compliance and container closure integrity across shelf life set the specification. Start with vial closures for biologics, then multidose vaccine vial seals for colour coding and fast access, and sealing lyophilised vials after freeze-drying, where the seal is crimped over a two-position lyophilisation stopper. Cell and gene therapy closures sit at the far end of the same group, where vials go to vapour-phase liquid nitrogen or -80 °C and a single autologous batch is one patient’s only dose.

Sterile injectables in volume. Products where line economics, repeated access and the sterilisation route shape the choice: IV diluent and saline vial closures, anaesthetic vial seals and colour differentiation, insulin and hormone closures for repeated puncture, and emergency and crash-cart drug seals, where the closure has to open single-handed in seconds and the colour has to separate look-alike strengths.

Specialty and high-risk fills. Applications where the closure carries a safety or handling burden on top of the sterile barrier: cytotoxic and oncology vial seals, ophthalmic closures on 13 mm necks, and contrast media seals built for power-injector spiking. Secondary packaging for prefilled syringes covers the adjacent format, where a vial travels in a kit alongside a syringe and the carton, tray and cold-chain design carry as much weight as the closure.

Diagnostics, reagents and animal health. A different regulatory pathway, but identification and handling still drive the closure: diagnostic and IVD reagent vial seals, research reagent closures for freeze-thaw duty, and veterinary seals for large multidose vials.

If you are choosing between formats rather than by drug type, the read-outs on single-dose versus multi-dose vials and 13 mm versus 20 mm caps cover the two decisions that come up most often, and how to choose a vial cap size works through matching the seal to the vial neck finish.

A note on standards

Whatever the application, the same closure standards apply. Autofits aluminium-plastic seals are designed to ISO 8362-6, the standard for caps made of aluminium-plastics combinations for injection vials, with vial necks following ISO 8362-1. All-aluminium seals relate to ISO 8362-3. Production runs under ISO 15378:2017, the GMP standard for primary packaging materials. For the sterile barrier itself, container closure integrity is evaluated against USP <1207>, and aseptic-filling expectations, including the CCI requirement for sterile products, are set by EU GMP Annex 1. These cut across every application below; the application pages note only where a standard carries extra weight for that product type. Two standards sit slightly outside that common set and matter to specific fills: USP <788> particulate matter for ophthalmic and oncology products, and BSE and TSE compliance where animal-derived materials are in scope, which is a live question for veterinary lines.

FAQ

Why does the drug product affect which vial seal I choose?

The seal always forms the sterile barrier the same way, by crimping the aluminium shell to compress the stopper. The product determines the secondary requirements: a multidose vaccine needs fast opening and tamper evidence, a biologic needs material compliance and proven container closure integrity, a lyophilised product needs a clean crimp on a part-seated stopper. Matching those requirements is what application-led selection means.

What is the default closure for most injectable applications?

For most liquid and lyophilised injectables the FlipTop® Optima flip-off seal in 13 mm or 20 mm is the default. You flip the plastic button to expose a central injection point while the aluminium stays crimped. Specific applications, such as oral vaccinations or products needing full stopper removal, point to the Tear-Down or Pull-Ring designs instead.

Which seal sizes are most common?

The 20 mm neck is the highest-volume size for injectable vials, and 13 mm is common for smaller-volume products such as some vaccines, biologics and ophthalmics. Larger parenterals, diluents and infusion-style vials use 28, 32 and 34 mm. Match the seal to the vial finish and the stopper of the same nominal diameter.

Do all these applications use the same standards?

Yes, broadly. ISO 8362-6 governs the aluminium-plastic cap design, ISO 15378 governs the GMP quality system, and USP <1207> with EU GMP Annex 1 cover container closure integrity and aseptic expectations. The application pages call out where one of these matters most for a given product.

Where can I see closures for a specific application?

Every drug category in the table has its own page. The deepest coverage is on biologics and IV diluents and saline; the most recent additions are cell and gene therapy, emergency drugs and prefilled syringe secondary packaging. For a closure-first view rather than a product-first one, start from the products page, browse by neck size from the by-size index, or send us the fill and the neck finish and we will come back with a specification.

Sources

Autofits FlipTop Seals dossier and engineering drawings (working/spec-sheets/)
ISO: ISO 8362-6:2010, Injection containers and accessories, Part 6: Caps made of aluminium-plastics combinations for injection vials (https://www.iso.org/standard/45641.html)
ISO: ISO 15378:2017, Primary packaging materials for medicinal products, GMP requirements (https://www.iso.org/standard/70729.html)
USP-NF: General Chapter <1207>, Package Integrity Evaluation, Sterile Products (https://www.usp.org/)
EudraLex Volume 4, EU GMP Annex 1, Manufacture of Sterile Medicinal Products (https://health.ec.europa.eu/)

*Last updated: 2026-06-27. This page is general technical information, not regulatory or compliance advice; confirm current standard editions and your own specification with Autofits and the issuing bodies.*